M. Ohori

972 total citations
10 papers, 385 citations indexed

About

M. Ohori is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, M. Ohori has authored 10 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Surgery and 2 papers in Molecular Biology. Recurrent topics in M. Ohori's work include Prostate Cancer Diagnosis and Treatment (4 papers), Prostate Cancer Treatment and Research (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). M. Ohori is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (4 papers), Prostate Cancer Treatment and Research (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). M. Ohori collaborates with scholars based in United States, Japan and Australia. M. Ohori's co-authors include Peter T. Scardino, Thomas M. Wheeler, Manish I. Patel, Ernesto Lopez‐Corona, Michael W. Kattan, Jeremy Goad, Shu‐Jen Chang, Gustavo Ayala, Rile Li and Anna Frolov and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and The American Journal of Surgical Pathology.

In The Last Decade

M. Ohori

10 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Ohori United States	5	309	105	83	73	65	10	385
Christopher L. Amling United States	6	330 1.1×	66 0.6×	59 0.7×	125 1.7×	37 0.6×	7	360
Andrea Hiltz Canada	3	362 1.2×	68 0.6×	88 1.1×	42 0.6×	24 0.4×	4	407
Sacha Wolf United States	4	442 1.4×	151 1.4×	80 1.0×	66 0.9×	27 0.4×	6	475
Kelly E. Maloney United States	8	198 0.6×	82 0.8×	53 0.6×	50 0.7×	32 0.5×	11	297
Ahmed Elshafei United States	12	426 1.4×	116 1.1×	39 0.5×	150 2.1×	50 0.8×	49	502
Neophytos Petrides United Kingdom	5	379 1.2×	102 1.0×	65 0.8×	92 1.3×	23 0.4×	9	455
Stijn H. de Vries Netherlands	10	300 1.0×	110 1.0×	68 0.8×	37 0.5×	38 0.6×	13	346
Mark Fallick United States	7	217 0.7×	115 1.1×	43 0.5×	50 0.7×	105 1.6×	29	315
Mary Achim United States	12	271 0.9×	76 0.7×	48 0.6×	99 1.4×	16 0.2×	23	323
Ted O. Morgan United States	7	433 1.4×	230 2.2×	88 1.1×	272 3.7×	56 0.9×	10	633

Countries citing papers authored by M. Ohori

Since Specialization

Citations

This map shows the geographic impact of M. Ohori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Ohori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Ohori more than expected).

Fields of papers citing papers by M. Ohori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Ohori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Ohori. The network helps show where M. Ohori may publish in the future.

Co-authorship network of co-authors of M. Ohori

This figure shows the co-authorship network connecting the top 25 collaborators of M. Ohori. A scholar is included among the top collaborators of M. Ohori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Ohori. M. Ohori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Nakashima, Jun, et al.. (2012). 1020 Clinical variables for predicting stage IV renal cell carcinoma patients who will not benefit from cytoreductive nephrectomy. European Urology Supplements. 11(1). e1020–e1020a. 1 indexed citations

2.

Patel, Manish I., et al.. (2004). AN ANALYSIS OF MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER WHO DEFERRED DEFINITIVE THERAPY. The Journal of Urology. 171(4). 1520–1524. 154 indexed citations

3.

Li, Rile, Mamoun Younes, Thomas M. Wheeler, et al.. (2003). Expression of vascular endothelial growth factor receptor‐3 (VEGFR‐3) in human prostate. The Prostate. 58(2). 193–199. 70 indexed citations

4.

Cagiannos, Ilias, Markus Graefen, Pierre I. Karakiewicz, et al.. (2002). Analysis of Clinical Stage T2 Prostate Cancer: Do Current Subclassifications Represent an Improvement?. Journal of Clinical Oncology. 20(8). 2025–2030. 19 indexed citations

5.

Kattan, Michael W., et al.. (2001). Primary Gleason Pattern as a Predictor of Disease Progression in Gleason Score 7 Prostate Cancer. The American Journal of Surgical Pathology. 25(5). 657–660. 74 indexed citations

6.

Uchida, Τοyoaki, M. Ohori, & Shin Egawa. (2001). [Minimally invasive therapy for bladder and prostate cancer].. PubMed. 28(8). 1094–8. 4 indexed citations

7.

Matsumoto, Kazumasa, Masatsugu Iwamura, Tatsunori Satoh, et al.. (1999). [Extragonadal seminoma with testicular microlithiasis: a case report].. PubMed. 45(10). 725–7. 2 indexed citations

8.

Uchida, T., et al.. (1996). VLAP Versus TURP for BPH. Aktuelle Urologie. 27(S 1). 32–34. 1 indexed citations

9.

Goad, Jeremy, Shu‐Jen Chang, M. Ohori, & Peter T. Scardino. (1993). PSA AFTER DEFINITIVE RADIOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER. Urologic Clinics of North America. 20(4). 727–736. 59 indexed citations

10.

Kosaka, Ayumi, Hiroshi Matsumoto, & M. Ohori. (1988). [Evaluation of the correlation between serum sialic acid and various serum specific proteins].. PubMed. 36(6). 679–84. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact